Camson Bio Technologies Limited announced unaudited standalone earnings results for the second quarter and six months ended September 30, 2016. For the quarter, the company reported net sales/income from operations of INR 21.907 million against INR 122.562 million a year ago. Loss from operations before other income, finance costs & exceptional items was INR 48.826 million against loss of INR 6.336 million a year ago. Loss from ordinary activities before tax was INR 53.119 million against loss of INR 10.118 million a year ago. Net loss was INR 54.737 million or loss of INR 1.82 per basic and diluted share before and after extraordinary items against net loss of INR 6.272 million or loss of INR 0.021 per basic and diluted share before and after extraordinary items a year ago. For the six months, the company reported net sales/income from operations of INR 42.412 million against INR 264.923 million a year ago. Loss from operations before other income, finance costs & exceptional items was INR 110.360 million against profit of INR 4.415 million a year ago. Loss from ordinary activities before tax was INR 120.507 million against loss of INR 4.413 million a year ago. Net loss was INR 123.857 million or loss of INR 4.12 per basic and diluted share before and after extraordinary items against net loss of INR 6.805 million or loss of INR 0.23 per basic and diluted share before and after extraordinary items a year ago.